Plaintiffs Ask Court To Revisit Neurontin Ruling

Law360, New York (February 9, 2010, 6:15 PM EST) -- A group of plaintiffs has urged a federal court to reconsider a ruling that threw out Guardian Life Insurance Co. and Aetna Inc.’s claims in multidistrict litigation accusing Pfizer Inc. of improperly marketing anti-epilepsy drug Neurontin for off-label uses.

The class plaintiffs filed a bid with the U.S. District Court for the District of Massachusetts on Monday, claiming the court’s Jan. 8 ruling may have adopted a sweeping rule of law that could devastate private litigants’ ability to protect affordable health care from fraudulent marketing scams...
To view the full article, register now.